This really is impressive. How we can have a non-cash value of just $10-12M is beyond me. We have used the most suitable animal model available and achieved therapeutic results that are little short of astonishing and still the market has us pegged as a penny stock. Sure, we have not treated a patient in the clinic but these results are about as good as you can get in a pre-clinical setting. There are lots of deals done in the pre-clinical stages and so it beggars belief that no pharma wants to sponsor this program.
Pre-clinical success does not guarantee clinical success, far from it, but we could not wish for a better set of numbers going into the clinic. Even with more dilution on the way, shareholders should be happy that we do have a really good chance of having a commercial success with BB-301.
BLT Price at posting:
16.5¢ Sentiment: None Disclosure: Held
